Stock Taper
TVGNW
TEVOGEN BIO HOLDINGS INC.
NASDAQ
$0.05
▲ UP 2.49% (0.00)

KEY STATISTICS

Market Cap$11.10 M
52w High$0.05
52w Low$0.04
Dividend Yield
Frequency
P/E-0.02
Volume257.53K
Shares Out.207.42M

COMPANY

LEADERSHIP

Ryan H. Saadi
CHIEF EXECUTIVE
Ryan H. Saadi

COMPENSATION 2026

Salary$501,000
Stock Awards$9,920,000
Incentive Plan Pay$0
All Other Comp.$0
Total$10,421,000

ABOUT

SECTOR
Healthcare
WENT PUBLIC
February 15, 2024
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
18

UPCOMING EARNINGS

DateNov 24, 2026
DayTuesday
Rev. Est.
NOV
24
TUE

PRICE

$0.05 ▲ UP 2.49% (+$0.00)
$0.05$0.05$0.05$0.059:31 AM10:35 AM11:40 AM12:45 PM1:49 PM2:53 PM3:58 PM0.05

About Tevogen Bio Holdings Inc.

https://tevogen.com ↗

Tevogen Bio Holdings Inc., a Warren-based clinical-stage biotech, develops off-the-shelf T cell therapies for virology, oncology, and neurology, with its lead product TVGN 489 targeting acute COVID-19 and long COVID patients.

INDUSTRY

Biotechnology

A PRODUCT TEVOGEN BIO HOLDINGS INC. IS KNOWN FOR

TVGN-489
TVGN-489

Tevogen Bio's lead clinical-stage, off-the-shelf T cell therapy, which has completed Phase 1 for high-risk COVID-19 and is being developed for Long COVID, is the company's primary therapeutic focus.

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

DIRECTOR
Goh Keow Lin
Purchase · 40.0K shares
2026-07-10
DIRECTOR, 10 PERCENT OWNER, OFFICER: CHIEF EXECUTIVE OFFICER
Saadi Ryan H.
Purchase · 1.2M shares
2026-07-10
DIRECTOR
PODLOGAR SUSAN M
Purchase · 40.0K shares
2026-07-10
DIRECTOR
Patton Curtis L.
Purchase · 40.0K shares
2026-07-10

SECTORS PEERS

PEERPRICE
DWTX$2.65COMPARE
CING$5.33COMPARE
MRKR$1.37COMPARE
COCP$1.10COMPARE
PHIO$1.13COMPARE
INAB$1.03COMPARE
IMRN$1.15COMPARE
EVGN$0.55COMPARE